Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][5] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][39] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][39] - Empasiprubart, a novel monoclonal antibody, is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) [29] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][39] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin to VYVGART Hytrulo, aiming to enhance patient outcomes [39] Group 4: Presentation Details - The presentations at the AAN Annual Meeting will include various studies on myasthenia gravis and CIDP, showcasing the breadth of research and data supporting VYVGART and its pipeline candidates [4][6][7]

Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2][36] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][6] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [5][6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][38] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][38] - Empasiprubart is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) and delayed graft function following kidney transplant [28][36] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][38] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin (IVIg) to VYVGART Hytrulo, aiming to enhance patient outcomes [3][38]